720 related articles for article (PubMed ID: 21335144)
21. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study.
Nuzzi R; Tridico F
Semin Ophthalmol; 2015 Mar; 30(2):129-35. PubMed ID: 24171832
[TBL] [Abstract][Full Text] [Related]
22. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
[TBL] [Abstract][Full Text] [Related]
23. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
24. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP
Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
[TBL] [Abstract][Full Text] [Related]
25. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
26. Antivascular endothelial growth factors in age-related macular degeneration.
Schmidt-Erfurth U; Pollreisz A; Mitsch C; Bolz M
Dev Ophthalmol; 2010; 46():21-38. PubMed ID: 20703030
[TBL] [Abstract][Full Text] [Related]
27. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
[TBL] [Abstract][Full Text] [Related]
28. Pegaptanib for wet macular degeneration.
Fraunfelder FW
Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
[TBL] [Abstract][Full Text] [Related]
29. Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.
Ziemssen F; Sobolewska B; Deissler H; Deissler H
Expert Opin Drug Saf; 2016 Jan; 15(1):75-87. PubMed ID: 26568279
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab for neovascular ocular diseases.
Lynch SS; Cheng CM
Ann Pharmacother; 2007 Apr; 41(4):614-25. PubMed ID: 17355998
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of neovascular age-related macular degeneration with bevacizumab].
Monzón Moreno A
Farm Hosp; 2006; 30(6):387-8. PubMed ID: 17298199
[No Abstract] [Full Text] [Related]
32. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of neovascular age-related macular degeneration with antiangiogenic drugs].
Rodrigues EB; Rossi EE; Grumann Junior A; Meyer CH; Ho AC
Arq Bras Oftalmol; 2006; 69(5):756-65. PubMed ID: 17187150
[TBL] [Abstract][Full Text] [Related]
34. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
[TBL] [Abstract][Full Text] [Related]
35. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
Bressler SB
Ophthalmology; 2009 Oct; 116(10 Suppl):S1-7. PubMed ID: 19800534
[TBL] [Abstract][Full Text] [Related]
36. Neovascular age-related macular degeneration.
Veritti D; Sarao V; Lanzetta P
Ophthalmologica; 2012; 227 Suppl 1():11-20. PubMed ID: 22517121
[TBL] [Abstract][Full Text] [Related]
37. Pegaptanib sodium for the treatment of age-related macular degeneration.
Apte RS
Expert Opin Pharmacother; 2008 Feb; 9(3):499-508. PubMed ID: 18220500
[TBL] [Abstract][Full Text] [Related]
38. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use.
Thulliez M; Angoulvant D; Pisella PJ; Bejan-Angoulvant T
JAMA Ophthalmol; 2018 May; 136(5):557-566. PubMed ID: 29566105
[TBL] [Abstract][Full Text] [Related]
39. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
40. [VEGF inhibitors in ophthalmology].
Thys J; Dupont G; Rakic JM
Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
